In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of *Pseudomonas aeruginosa*

Yi-Fan Hu¹², Chang-Pan Liu¹²³⁴⁵*, Nai-Yu Wang² and Shou-Chuan Shih²³⁴⁵⁶*

**Abstract**

**Background:** Multidrug-resistant *Pseudomonas aeruginosa* has emerged as one of the most important healthcare-associated pathogens. Colistin is regarded as the last-resort antibiotic for multidrug-resistant Gram-negative bacteria, but is associated with high rates of acute kidney injury. The aim of this in vitro study is to search for an alternative treatment to colistin for multidrug-resistant *P. aeruginosa* infections.

**Methods:** Multidrug and carbapenem-resistant *P. aeruginosa* isolates were collected between January 2009 and December 2012 at MacKay Memorial Hospital. Minimal inhibitory concentrations (MICs) were determined for various antibiotic combinations. Carbapenemase-producing genes including *bla*⁴₆, other β-lactamase genes and porin mutations were screened by PCR and sequencing. The efficacy of carbapenems (imipenem, meropenem, doripenem) with or without rifampicin was correlated with the type of porin mutation (frameshift mutation, premature stop codon mutation) in multidrug-resistant *P. aeruginosa* isolates without carbapenemase-producing genes.

**Results:** Of the 71 multidrug-resistant clinical *P. aeruginosa* isolates, only six harboured the *bla*⁴₆ gene. Imipenem, meropenem and doripenem were significantly more effective (reduced fold-change of MICs) when combined with rifampicin in *bla*⁴₆-negative isolates, especially in isolates with porin frameshift mutation.

**Conclusions:** Imipenem + rifampicin combination has a low MIC against multidrug-resistant *P. aeruginosa*, especially in isolates with porin frameshift mutation. The imipenem + rifampicin combination may provide an alternative treatment to colistin for multidrug-resistant *P. aeruginosa* infections, especially for patients with renal insufficiency.

**Keywords:** Frameshift mutation, Imipenem, Porin mutation, *Pseudomonas aeruginosa*, Rifampicin

**Abbreviations:** CLSI, Clinical and Laboratory Standards Institute; Cr, Creatinine; eGFR, Estimated glomerular filtration rate; MDR, Multidrug resistant; MIC, Minimal inhibitory concentration; PCR, Polymerase chain reaction; PFGE, Pulsed-field gel electrophoresis

---

**Background**

*Pseudomonas aeruginosa* is one of the leading pathogens causing healthcare-associated infections. Besides being innately resistant to a myriad of antibiotics used to treat Gram-negative infections, a number of *P. aeruginosa* isolates has been acquiring multidrug resistance (MDR) at an alarming rate, raising much clinical concern. Carbapenems are an important class of antimicrobial agents used to treat *P. aeruginosa* infections [1]; as such, the acquisition of resistance against carbapenems in many *P. aeruginosa* isolates is especially worrisome.

Development of multidrug resistance in *P. aeruginosa* is common, especially when antibiotics exert strong selective pressure on bacterial populations [2, 3]. The resistant mechanisms of multidrug-resistant *P. aeruginosa* include acquisition of carbapenemase gene, inactivation of oprD causing outer-membrane impermeability, and expression...
of broadly specific multidrug efflux pump systems [2, 3]. Resistance to carbapenem is commonly observed among 
*P. aeruginosa* isolates and is frequently associated with decreased expression or loss of function of oprD, which leads to outer-membrane impermeability [2, 4]. Reduced permeability due to loss of oprD leads to a four- to 16-fold increase in the minimum inhibitory concentrations (MICs) for carbapenems in *P. aeruginosa* [3, 4].

Polymyxin antibiotics have been used clinically since the 1960’s and exert activity against many MDR Gram-negative bacteria in vitro, including *P. aeruginosa* and Acinetobacter baumannii. Currently, two polymyxin antibiotics are commercially available for clinical use - colistin and polymyxin B - which differ in structure by only one amino acid [5]. Carbapenems are usually prescribed for severe *P. aeruginosa* infections; however, colistin is the only antibacterial agent that currently exerts activity against *P. aeruginosa* strains that are highly resistant to carbapenems [6]. However, nephrotoxicity is a major dose-limiting adverse effect of both polymyxin B and colistin, with rates of acute kidney injury ranging from 30 to 60 % as reported in recent studies [7–9]. The potential nephrotoxicity of colistin is a clinical concern, especially in patients with renal insufficiency.

Although imipenem inhibits most bacterial growth at very low concentrations, some *P. aeruginosa* strains are resistant or become resistant after exposure [10]. Combined antibiotic therapy for invasive *P. aeruginosa* is used in many health care facilities [10, 11]. In vitro studies suggest that rifampicin-based regimens exert synergistic activity when used as part of a combination therapy regimen against carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae* [12]. Rifampicin acts to inhibit bacterial DNA-dependent RNA polymerase, which suppresses initial chain formation during RNA synthesis. Alterations to the beta subunit of bacterial DNA-dependent RNA polymerase result in resistance to rifampicin.

The aim of this study was to search for an alternative, combined treatment for multidrug-resistant *P. aeruginosa* infections, in order to avoid the use of colistin and therefore prevent acute kidney injury, especially in patients with renal insufficiency. We assessed the effects of various combinations of antimicrobial agents on multidrug-resistant clinical *P. aeruginosa* isolates. This in vitro data may be useful for supporting therapeutic decisions for patients with severe infections caused by multidrug-resistant *P. aeruginosa*.

**Methods**

**Collection of bacterial isolates**

With the approval of the Institutional Review Board (protocol number 13MMHIS218), clinical isolates of multidrug and carbapenem-resistant *P. aeruginosa* as identified by the Vitek 2 system ((bioMérieux Vitek Systems Inc., Hazelwood, MO, USA) were collected at MacKay Memorial Hospital, a 2200-bed tertiary teaching hospital in Taiwan, between January 2009 and December 2012. The isolates were confirmed as *P. aeruginosa* using the Vitek 2 system again in a microbiology laboratory. Multidrug resistance is defined as resistance to three or more classes of antibiotics. Carbapenem resistance is defined as minimal inhibitory concentration (MIC) of imipenem ≥ 8 mg/L in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines [13]. Isolates were stored in trypticase soy broth (BD, MD, USA) containing 20 % glycerol (v/v) under −70 °C until further analysis.

**Estimated glomerular filtration rate (eGFR) and creatinine (Cr) level**

Patients were classified according to estimated glomerular filtration rate (eGFR) and creatinine (Cr) levels. An estimated glomerular filtration rate ≥ 60 mL/min was classified as eGFR level 1 group; those between 30 to 60 mL/min (30 mL/min ≤ eGFR < 60 mL/min) was classified as level 2, and those <30 mL/min was classified as level 3. Cr level 1 group was defined as serum creatinine level less than 1.5 mg/dL; Cr level 2 group was between 1.5 and 3 (1.5 mg/dL ≤ Cr < 3 mg/dL), and the Cr level 3 group was defined as a serum creatinine level greater than or equal to 3 (Cr ≥3 mg/dL). Renal insufficiency was defined as an eGFR of less than 60 mL/min.

**Antimicrobial susceptibility testing**

The antimicrobial susceptibility test of all 71 clinical isolates was determined both by an automated method performed by Vitek2 system and by manual agar dilution method [14]. In the agar dilution method, the effect of individual antibiotics was measured in different concentrations, including 0.03–128 mg/L of ceftazidime, 0.03–128 mg/L of imipenem, 0.03–128 mg/L of meropenem and 0.03–128 mg/L of doripenem. The effect of various combinations of antibiotics was measured by the addition of 4 mg/L tazobactam, 8 mg/L phosphomycin, 8 mg/L sulbactam, 10 mg/L rifampicin, or 20 mg/L rifampicin to various concentrations of ceftazidime, imipenem, meropenem, and doripenem. The MICs were interpreted according to CLSI guidelines [13].

**Phenotypic detection of production of carbapenemase**

The production of carbapenemase were screened by the Carba NP test [15]. The Carba NP test is faster and more specific than the modified Hodge test [13], and is therefore more convenient and rapid in the clinical setting.

Briefly, 30 μL of the supernatants of the enzymatic bacterial suspension was mixed with 100 μL aliquots of a 1 mL solution containing 3 mg imipenem monohydrate (USP; Twinbrook Parkway, Rockville, MD, USA), phenol red solution (Merck Millipore, Billerica, MA, USA) and
0.1 mmol/L ZnSO₄ (Merck Millipore) at pH 7.8. The phenol red solution was prepared by mixing 2 mL of a phenol red solution 0.5 % (wt/vol) with 16.6 mL of distilled water. The mixtures were incubated at 37 °C for a maximum of 2 h. Red or red-orange of Carba NP test was interpreted as negative while yellow or light orange was interpreted as a positive result.

**Phenotypic detection of hyperexpression of efflux pumps and cephalosporinase activity**

Imipenem, meropenem and doripenem MIC values were determined in the presence of the efflux pump inhibitor phenyl-arginine-β-naphthylamide (PAβN; at 100 mg/L) and the cephalosporinase (AmpC) inhibitor cloxacillin (at 250 mg/L) [1].

**Polymerase chain reaction and sequencing**

The *P. aeruginosa* isolates were screened for carbapenem-producing genes *bla*IMB, *bla*VIM, *bla*NDM, *bla*KPM, *bla*AXIM, *bla*DIM, *bla*SIM, *bla*KPC, *bla*OXA, and Class D genes (*bla*OXA-group I, *bla*OXA-group II and *bla*OXA-group III) [16] and *oprD* gene mutations [17] using polymerase chain reaction (PCR) and sequencing. Briefly, the bacterial isolates were boiled in sterile water for 10 min, and the supernatants were used for PCR; each 25 μL 2x Hot Master Mix (JMR, Sevenoaks Kent, UK) consisted of 1x S-T Gold buffer, 1.5 mM MgCl₂, 0.2 mM dNTPs and 20 pmol of each primer. The PCR amplicons were purified using ExoSAP-IT reagent (USB, Cleveland, OH, USA) and both strands were sequenced using the standard dideoxy nucleotide method in an ABI Prism 377 DNA sequencer (Applied Biosystems, Foster City, CA, USA). Sequence similarity searches were performed with the basic local alignment search tool (BLAST; http://blast.ncbi.nlm.nih.gov/Blast.cgi).

**Pulsed-field gel electrophoresis**

The isolates of 71 multidrug-resistant *P. aeruginosa* were typed by pulsed-field gel electrophoresis (PFGE) following digestion of intact genomic DNA with SpeI (Biolabs, Beverly, MA, USA). The DNA fragments were separated on 1 % (w/v) SeaKem GTG agarose gels in 0.5 % Trisborate-ethylene diamine tetra-acetic acid TBE buffer using a CHEF Mapper apparatus (Bio-Rad, Hercules, CA, USA) at a potential of 6 V/cm pulsed from 5 to 35 s for 22 h at 14 °C [18]. The gels were stained with ethidium bromide and photographed under ultraviolet light. The SpeI restriction profiles were initially compared by visual inspection and isolates were considered to be closely related if they showed differences of less than three bands [19]. Computer-assisted analysis using BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium) was also performed. Cluster analysis was performed by the unweighted pair group method with mathematical averaging, and DNA relatedness was calculated using the band-based Dice coefficient with a tolerance setting of 1.0 % and 1.0 % optimization setting for the whole profile [20]. Isolates were considered to belong to the same cluster if the similarity coefficient was >80 % [21].

**Results**

**Patient characteristics**

In total, isolates were collected from 71 patients admitted to MacKay Memorial Hospital with multidrug-resistant *P. aeruginosa* infections. The male-to-female ratio was 44:27 (males, 61.97 %; 44/71). The age distribution of the male population was 73.80 ± 12.64 years; the age distribution of the female population was 75.00 ± 15.69 years. The overall mortality rate was 32.39 % (23/71), 31.82 % (14/44) in males and 33.33 % (9/27) in females.

The sources of multidrug-resistant *P. aeruginosa* infections were bacteremia (21/71; 29.58 %), urinary tract infection (18/71; 25.35 %), respiratory infection (13/71; 18.31 %), wound infection (8/71; 11.27 %), tip of catheters (5/71; 7.04 %), drain discharge (4/71; 5.63 %), ascites (1/71; 1.41 %), and pleural effusion (1/71; 1.41 %).

**Estimated glomerular filtration rate (eGFR) and creatinine (Cr) level**

57.75 % (41/71) of the patients in this study had renal insufficiency. In total, 42.25 % (30/71) of patients were classified as eGFR level 1 (eGFR ≥60 mL/min), 9.86 % (7/71) were placed in eGFR group 2 (30 mL/min ≤ eGFR < 60 mL/min), and 47.89 % (34/71) belonged to eGFR group 3 (eGFR <30 mL/min). When classified by the creatinine (Cr) levels, 49.30 % (35/71), 15.49 % (11/71), and 35.21 % (25/71) of patients were in Cr level 1 (Cr <1.5 mg/dL), the Cr level 2 (1.5 mg/dL ≤ Cr < 3 mg/dL), and the Cr level 3 (Cr ≥3 mg/dL) groups, respectively.

**Resistance of the isolates to antibiotic monotherapy and combinations in vitro**

Of the 71 multidrug-resistant *P. aeruginosa* isolates collected, 85.92 % (61/71) were susceptible to amikacin (MIC ≤16 mg/L); none (0/71) was susceptible to ceftazidime (MIC ≤8 mg/L), imipenem (MIC ≤2 mg/L) or meropenem (MIC ≤2 mg/L). Only 1.41 % (1/71) were susceptible to doripenem (MIC ≤2 mg/L), and 98.59 % (70/71) were susceptible to colistin (MIC ≤2 mg/L). There was no significant difference in the MICs of most monotherapies compared to the combined therapies, as shown in Table 1. These combination therapies included 0.03–128 mg/L ceftazidime plus 4 mg/L tazobactam, 8 mg/L phosphomycin, or 8 mg/L sulbactam respectively. The three carbapenems (imipenem, meropenem, and doripenem) with various concentrations from 0.03 to 128 mg/L were included in the combined therapies, as shown in Table 1.
Rifampicin alone was not effective (MICs ranging from 16 to 128 mg/L) against any of the 71 isolates. However, 0.03–128 mg/L imipenem + 20 mg/L rifampicin, 0.03–128 mg/L meropenem + 20 mg/L rifampicin, and 0.03–128 mg/L doripenem + 20 mg/L rifampicin had lower MICs compared to each individual carbapenem alone against multidrug-resistant *P. aeruginosa* clinical isolates. Imipenem + 20 mg/L rifampicin showed good activity, similar to that of meropenem + 20 mg/L rifampicin and doripenem + 20 mg/L rifampicin. Each carbapenem combined with 20 mg/L rifampicin exerted synergy in vitro, indicating that carbapenems combined with 20 mg/L rifampicin may represent a potential combination therapy against highly multidrug-resistant *P. aeruginosa* infections.

**Carbapenemase-producing isolates**
Six of the 71 isolates (8.45 %) were also positive for the Carba NP test. Subsequently, PCR and sequencing indicated that all isolates positive for the Carba NP test harboured the bla<sub>VIM</sub> gene, with 7.04 % (5/71) having the bla<sub>VIM-2</sub> gene and 1.41 % (1/71) with the bla<sub>VIM-3</sub> gene.

**PFGE analysis of the P. aeruginosa isolates without Carbapenemase-producing gene**
The similarity of all 71 multidrug-resistant *P. aeruginosa* isolates with or without the bla<sub>VIM</sub> gene was demonstrated in Fig. 1. Thirty-six PFGE patterns were classified from 65 multidrug-resistant *P. aeruginosa* isolates without the bla<sub>VIM</sub> gene. The remaining six isolates with bla<sub>VIM</sub> genes belonged to other three pulsotypes; the results were demonstrated in Fig. 1.

**Antibiotic combination for P. aeruginosa isolates with and without carbapenemase-producing gene**
Excluding six bla<sub>VIM</sub>-producing isolates, there remained 65 isolates from 71 multidrug-resistant *P. aeruginosa*. The percentage of the 65 multidrug-resistant *P. aeruginosa* isolates for which combined treatment with 20 mg/L rifampicin resulted in lower MICs than imipenem, meropenem or doripenem alone is shown in Table 2. The isolates are classified by the presence or absence of the bla<sub>VIM</sub> determinant and shown as the percentage of NR (non-resistant) or S (sensitive) isolates for each carbapenem in the presence or absence of rifampicin. No significant differences in the percentage of NR (non-resistant) or S (sensitive) isolates were observed between imipenem and rifampicin, meropenem and rifampicin, and doripenem and rifampicin compared to the individual carbapenems alone in the six isolates with the bla<sub>VIM</sub> determinant.

However, imipenem + 20 mg/L rifampicin was the most effective combined therapy in vitro (versus any other carbapenem combination) against the 65 multidrug-resistant *P. aeruginosa* isolates that did not harbour the bla<sub>VIM</sub> determinant. None of the 65 isolates without the bla<sub>VIM</sub> determinant were sensitive to imipenem alone whereas 86.15 % (56/65) were non-resistant to imipenem combined with 20 mg/L rifampicin (Table 2).

Figure 2 shows the percentages of the 65 multidrug-resistant *P. aeruginosa* isolates without the bla<sub>VIM</sub> determinant for which combined therapy with rifampicin resulted in lower MICs compared to imipenem, meropenem or doripenem alone. In accordance with a previous report [10] and as expected, imipenem + 20 mg/L rifampicin was confirmed as the most effective therapy against the multidrug-resistant clinical *P. aeruginosa* isolates in vitro.

**Phenotyping detection of hyperexpression of efflux pumps and cephalosporinase activity**
MIC values of carbapenem agents were considerably reduced in the presence of the efflux inhibitor Pa<sub>B</sub>N. Application of Pa<sub>B</sub>N to multidrug-resistant *P. aeruginosa* isolates resulted in ≥2-fold decrease in MIC values for 95.38 % (62/65) of the isolates for imipenem, 87.69 % (57/65) of the isolates for meropenem, and 96.92 % (63/65) of the isolates for doripenem. This efflux pump inhibitor (Pa<sub>B</sub>N) showed greater inhibitory activity when combined with imipenem, lowering 46.15 % (30/65), 35.38 % (23/65), 6.15 % (4/65), 6.15 % (4/65), 0 % (0/65) and 1.54 % (1/65) of the MIC values by 2-fold, 4-fold, 8-fold, 16-fold, 32-fold and 64-fold dilution, respectively. This efflux pump inhibitor (Pa<sub>B</sub>N) showed greater inhibitory activity when combined with meropenem, lowering 12.31 % (8/65), 32.31 % (21/65), 41.54 % (27/65), 6.15 % (4/65), 6.15 % (4/65), 0 % (0/65) and 1.54 % (1/65) of the MIC values by 1-fold, 2-fold, 4-fold, 8-fold, 16-fold, 32-fold, 64-fold and 128-fold dilution, respectively. This efflux pump inhibitor (Pa<sub>B</sub>N) showed greater inhibitory activity when combined with doripenem, lowering 3.07 % (2/65), 27.69 % (18/65), 41.54 % (27/65), 20.00 % (13/65) and 7.69 % (5/65) of the MIC values by 1-fold, 2-fold, 4-fold, 8-fold and 16-fold.

---

**Table 1** MIC reduced fold-change of the multidrug-resistant *P. aeruginosa* isolates to various antibiotic combinations

| Antibiotic combinations | 0.03–128 mg/L ceftazidime | 0.03–128 mg/L imipenem | 0.03–128 mg/L meropenem | 0.03–128 mg/L doripenem |
|-------------------------|---------------------------|------------------------|------------------------|------------------------|
| 4 mg/L tazobactam       | No difference<sup>a</sup>  | No difference<sup>a</sup> | No difference<sup>a</sup> | No difference<sup>a</sup> |
| 8 mg/L phosphomycin     | No difference<sup>a</sup>  | No difference<sup>a</sup> | No difference<sup>a</sup> | No difference<sup>a</sup> |
| 8 mg/L sulbactam        | No difference<sup>a</sup>  | No difference<sup>a</sup> | No difference<sup>a</sup> | No difference<sup>a</sup> |

<sup>a</sup>No difference: No significant difference in the MIC reduced fold-change
dilution, respectively. It is noteworthy that a greater inhibitory effect was observed for imipenem, meropenem and doripenem when both efflux pump inhibitor (PAßN) and AmpC inhibitor (cloxacillin) were combined [100 % (65/65), 95.38 % (62/65) and 98.46 % (64/65) inhibition by ≥2-fold dilution].
Antibiotic combination for isolates with oprD gene mutation

The 65 multidrug-resistant *P. aeruginosa* isolates without the carbapenemase (*bla*<script>\text{VIM}</script>) determinant were screened for oprD gene mutations, and 21 isolates were classified as having a frameshift mutation while 39 isolates were classified as having premature stop codon mutation. Only five isolates were without an oprD mutation.

The percentages of isolates with each type of oprD gene mutation for which combined therapy with 20 mg/L rifampicin resulted in a lower MIC than the carbapenem alone is shown in Fig. 3. Combined therapy with rifampicin resulted in lower MICs in isolates with the frameshift oprD mutation than with the premature stop codon oprD mutation.

Discussion

Colistin is commercially available for clinical use; however, shortly after it was introduced clinically, reports of
nephrotoxicity led to a significant decline in its use [5]. Therefore, an alternative treatment for multidrug-resistant *P. aeruginosa* infections is required to avoid the acute kidney injury associated with colistin treatment, especially in patients with renal insufficiency. The treatment options for multidrug-resistant *P. aeruginosa* infections are limited and combination therapy with other antimicrobial agents has often been suggested as a potential strategy. In particular, synergism between colistin + rifampicin has been demonstrated in several studies and the addition of a carbapenem to this regimen may be an option, despite the apparent resistance of multidrug-resistant *P. aeruginosa* [22]. However, as yet there is no evidence-based support for most combination therapies against carbapenem-resistant Gram-negative bacteria including colistin/carbapenem combination therapy [23].

The aims of this study were to search for the most effective colistin-free combinations of antibiotics against multidrug-resistant *P. aeruginosa* isolates in vitro and investigate the effect of specific mutations in the isolates without carbapenemase-producing genes (i.e., the porin frameshift mutation and premature stop codon mutation) on combined therapy in multidrug-resistant *P. aeruginosa* clinical isolates.

Carbapenems have different levels of activity against *P. aeruginosa* isolates. In vitro studies by Kanj et al. [12] showed that doripenem had the lowest MICs, followed by meropenem and imipenem. Goyal et al. reported that doripenem had an 84.2-fold lower MIC towards *P. aeruginosa* isolates (0.38 mg/L) than meropenem (>32 mg/L) [24]. In agreement with these previous results, doripenem had lower MICs than meropenem in the 71 multidrug-resistant *P. aeruginosa* isolates. However, 65 of the 71 multidrug-resistant *P. aeruginosa* isolates had doripenem MIC values >2 mg/L, with a high percentage of isolates non-susceptible to imipenem, meropenem and doripenem.

It is widely accepted that rifampicin should not be used as a monotherapy in order to avoid the development of rifampicin resistance [25]. In addition, Morris et al. reported that the MICs for rifampicin in most aerobic gram-negative bacilli were <12 mg/L, although MICs as high as 32 mg/L have been observed for *P. aeruginosa* [26]. Several lines of evidence in this study support these previous reports. The MICs for rifampicin were high in the *P. aeruginosa* isolates: the frequency distribution of the MICs for the 65 multidrug-resistant *P. aeruginosa* isolates was as follows: 13.85 %, 16 mg/L; 70.77 %, 32 mg/L; 13.85 %, 64 mg/L; and 1.54 %, 128 mg/L. Therefore, we investigated whether combined treatments could effectively inhibit multidrug-resistant *P. aeruginosa*.

Rifampicin can inhibit DNA-dependent RNA polymerase activity in susceptible *Mycobacterium tuberculosis* organisms [26]. Majewski et al. previously demonstrated that in vitro synergism or an additive interaction between rifampicin and imipenem occurred in *A. baumannii* strains showing resistance to imipenem [25]. In agreement with the data in this study, imipenem + 20 mg/L rifampicin, meropenem + 20 mg/L rifampicin, and doripenem + 20 mg/L rifampicin resulted in significantly lower MICs than the individual monotherapies alone. The performance of imipenem + 20 mg/L rifampicin combination was especially well.
An unexpected finding in this study was that the imipenem + rifampicin combination only showed bacteriostatic effects against *P. aeruginosa* isolates in vitro, and was not any more effective (than the individual monotherapies) against the six isolates harbouring the *bla*<sub>VIM</sub> determinant. Therefore, we further investigated the activity of carba-
penem + 20 mg/L rifampicin against the 65 *P. aeruginosa* isolates that did not harbour the *bla*<sub>VIM</sub> gene.

A number of studies have found that the most prevalent intrinsic mechanism of multidrug-resistance in *P. aeruginosa* is inactivation of *oprD* [1, 3, 27]. Riera et al. revealed that imipenem resistance was driven by *oprD* inactivation, while *ampC* overexpression and, in particular, efflux pump hyperproduction had a lower impact on the activity of doripenem compared to meropenem among *P. aeruginosa* [27]. Vatcheva-Dobrevska et al. revealed that nearly all of

---

**Fig. 4** MIC values of multidrug-resistant *P. aeruginosa* isolates to imipenem between with or without 20 mg/L rifampicin, stratified as (a) The 21 isolated with a frameshift porin mutation; (b) The 39 isolates with a premature stop codon porin mutation.
29 multidrug-resistant \textit{P. aeruginosa} isolates (97\%) lacked OprD production, whereas only five isolates (17.24\%) overexpressed \textit{ampC} \cite{28}. Fournier et al. demonstrated that the porin OprD was lost in 94 (86.2\%) of isolates \cite{3}. Castanheira et al. illustrated that \textit{oprD} decrease/loss was the most prevalent intrinsic mechanism of carbapenem-resistance (94.9\% of \textit{P. aeruginosa} isolates), followed by \textit{ampC} overexpression (44.4\%) \cite{1}. In line with these previous reports, 92.31\% (60/65) of the isolates tested in this study had \textit{oprD} mutations.

To our knowledge, this is the first study designed to compare the combined activities of imipenem + rifampicin in multidrug-resistant \textit{P. aeruginosa} concerning the types of porin mutations. We evaluated the efficacy of imipenem + rifampicin in isolates with porin frameshift mutation and premature stop codon mutation. Imipenem combined with 20 mg/L rifampicin was significantly more effective in the isolates with the porin frameshift mutation.

Our results and those of others clearly demonstrate the in vitro efficacy of the imipenem + rifampicin combination \cite{10}, which may be due to a synergistic effect against multidrug-resistant \textit{P. aeruginosa} isolates with porin mutations and without \textit{bla}_{\text{VIM}} producing genes. However, we cannot explain why the combination of imipenem + rifampicin exhibited a significantly higher efficacy in the isolates with a porin frameshift mutation. Interestingly, we also observed that the addition of 10 mg/L rifampicin to different concentrations of imipenem, meropenem or doripenem did not reduce MIC in the 71 multidrug-resistant \textit{P. aeruginosa} clinical isolates.

This study provides valuable in vitro data on the MICs of various combinations of antibiotics on multidrug-resistant clinical \textit{P. aeruginosa} isolates. However, the clinical significance of these findings needs to be evaluated. Our data indicates that imipenem + 20 mg/L rifampicin represents a promising alternative combination therapy for patients with multidrug-resistant \textit{P. aeruginosa} infections; the use of such therapy obviates the need for colistin and the potential nephrotoxicity associated with its use, showing promise for patients with existing renal insufficiency. The combination of imipenem and rifampicin warrants further laboratory and clinical trials.

For providing quick clinical identification, we suggest that the Carba NP test should be used initially to screen for isolates harbouring carbapenemase-producing genes, and that rifampicin + imipenem combination therapy be used only for infections caused by multidrug-resistant \textit{P. aeruginosa} strains without the \textit{bla}_{\text{VIM}} determinant. The combination of rifampicin + imipenem demonstrated good efficiency in vitro against multidrug-resistant \textit{P. aeruginosa} isolates that do not harbour the \textit{bla}_{\text{VIM}} resistance gene, especially in isolates with a frameshift porin mutation. We must highlight the inherent limitations of this study in terms of its observational design and limited sample size.

Conclusions

The combination of rifampicin + imipenem demonstrated good efficiency in vitro against multidrug-resistant \textit{P. aeruginosa} isolates that do not harbour the \textit{bla}_{\text{VIM}} resistance gene, especially in isolates with a frameshift porin mutation. Carba NP test is a very useful tool to screen for \textit{P. aeruginosa} isolates that may be susceptible to the rifampicin + imipenem combination therapy, and can be easily and rapidly performed in most medical facilities. Imipenem + rifampicin could be an alternative treatment for multidrug-resistant \textit{P. aeruginosa} infections. Such combination therapy avoids the risk for acute kidney injury-induced by colistin, which is especially important in patients with renal insufficiency.

Acknowledgements

The authors thank Dr Alice Wu, M.D. for her assistance in revising the English.

Funding

This study was funded by the grant MMH103-33 from Mackay Memorial Hospital, Taipei, Taiwan.

Availability of data and materials

The data supporting the finding of this study is contained within the manuscript.

Authors' contributions

YFH and CPL conceived and designed the research. NYW carried out the laboratory work. YFH and CPL interpreted the data and drafted the manuscript. YFH, CPL and SCS participated in critical revision of the manuscript. All authors approved the final version.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This retrospective study was approved by the Institutional Review Board, Mackay Memorial Hospital, protocol no. 13MMHIS218.

Author details

1Division of Infectious Diseases, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.
2Department of Medical Research, Mackay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Road, Taipei, Taiwan.
3Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.
4Mackay College of Medicine, Nursing and Management, Taipei, Taiwan.
5Infection Control Committee, Mackay Memorial Hospital, Taipei, Taiwan.
6Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.

Received: 8 November 2015 Accepted: 16 August 2016
Published online: 24 August 2016

References

1. Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible \textit{Pseudomonas aeruginosa} collected during 2009–11 in 14 European and Mediterranean countries. \textit{J Antimicrob Chemother}. 2014;69(7):1804–14.
2. Trias J, Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of \textit{Pseudomonas aeruginosa}. \textit{Antimicrob Agents Chemother}. 1990;34(1):52–7.
3. Fournier D, Richardot C, Müller E, Robert-Nicoud M, Llanes C, Plesiat P, et al. Complexity of resistance mechanisms to imipenem in intensive care unit strains of \textit{Pseudomonas aeruginosa}. \textit{J Antimicrob Chemother}. 2013;68(8):1772–80.
et al. BMC Infectious Diseases (2016) 16:444

Pseudomonas aeruginosa

Acinetobacter baumannii

6. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect. 2012;65(1):80–7.

7. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zawaski AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014;43(4):369–52.

8. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53(9):879–84.

9. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect. 2012;65(1):80–7.

10. Chin NX, Neo HC. Synergy of imipenem—a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species. Chemotherapy. 1987;33(3):183–8.

11. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450–70.

12. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86(3):250–9.

13. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement, CLSI document M100-S25. Wayne: CLSI; 2015.

14. Clinical and Laboratory Standards Institutes. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. Ninth edition M07-A9. Wayne: CLSI; 2012.

15. Dortet L, Poirel L, Nordmann P. Rapid detection of carbapenemase-producing Pseudomonas spp. J Clin Microbiol. 2012;50(11):3773–6.

16. Mirsalehian A, Feizabadi M, Nakhjavani FA, Jabalameli F, Goli H, Kalantari N. Rapid detection of carbapenemase-producing Enterobacteriaceae in hospital outbreak driven by Acinetobacter harboring the VEB-1 resistance gene. Scand J Infect Dis. 2014;46(4):260–4.

17. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22(4):582–610.

18. Phe K, Lee Y, McDanel PM, Praaad N, Yin T, Figueroa DA, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;58(2):746–80.

19. Majewski P, Gwozdziewicz A, Traczyk M, Tyczynska M. Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2011;66(9):2022–7.

20. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33(9):2233–9.

21. van Mansfeld R, Jongerden I, Bootsma M, Buiting A, Bonten M, Willems R. The population genetics of Pseudomonas aeruginosa isolates from different patient populations exhibits high-level host specificity. PLoS One. 2010;5(10):e13482.

22. Morelli P, Ferrario A, Tordato F, Piazza A, Casari E. Successful treatment of infective endocarditis with combination therapy of colistin, rifampicin and doripenem. J Antimicrob Chemother. 2014;69(3):857–9.

23. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Tenover FC, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014;69(9):2305–9.

24. Goyal K, Gautam V, Ray P. Doripenem vs meropenem against Pseudomonas aeruginosa and Acinetobacter. Indian J Med Microbiol. 2013;30(3):350–1.

25. Majewski P, Wiecek P, Ojdana D, Schafer P, Wiecek A, Traczyk M, et al. Molecular epidemiology of Pseudomonas aeruginosa isolated from Bulgarian hospitals. Microb Drug Resist. 2013;19(5):355–61.

26. Morris AB, Brown RB, Sands M. Use of rifampin in nonstaphylococcal, nonmycobacterial disease. Antimicrob Agents Chemother. 1993;37(1):1–7.

27. Riera E, Cabot G, Mulet X, Garcia-Castillo M, del Campo R, Juan C, et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother. 2013;66(9):2022–7.

28. Vatcheva-Dobrevska R, Mulet X, Ivanov I, Zamarano L, Dobrevska E, Velinov T, et al. Molecular epidemiology and multidrug resistance mechanisms of Pseudomonas aeruginosa isolates from Bulgarian hospitals. Microb Drug Resist. 2013;19(5):355–61.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit